139 related articles for article (PubMed ID: 31414267)
1. Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug.
Chen J; Luo B; Wen S; Pi R
Invest New Drugs; 2020 Jun; 38(3):755-764. PubMed ID: 31414267
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
[TBL] [Abstract][Full Text] [Related]
4. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
[TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, in vitro and structural aspects of cap substituted Suberoylanilide hydroxamic acid analogs as potential inducers of apoptosis in Glioblastoma cancer cells via HDAC /microRNA regulation.
Mekala JR; Ramalingam PS; Mathavan S; Yamajala RBRD; Moparthi NR; Kurappalli RK; Manyam RR
Chem Biol Interact; 2022 Apr; 357():109876. PubMed ID: 35283086
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
10. MMP14 Contributes to HDAC Inhibition-Induced Radiosensitization of Glioblastoma.
Zhou Y; Liu H; Zheng W; Chen Q; Hu S; Pan Y; Bai Y; Zhang J; Shao C
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638754
[TBL] [Abstract][Full Text] [Related]
11. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Natural Flavonoid Curcumin Exhibits Anticancer and Antibacterial Activity.
Altundağ EM; Toprak K; Şanlıtürk G; Güran M; Özbilenler C; Kerküklü NR; Yılmaz AM; Yalçın AS
Anticancer Agents Med Chem; 2021; 21(10):1301-1308. PubMed ID: 33023457
[TBL] [Abstract][Full Text] [Related]
13. Synergism of 4HPR and SAHA increases anti-tumor actions in glioblastoma cells.
Khathayer F; Taylor MA; Ray SK
Apoptosis; 2020 Apr; 25(3-4):217-232. PubMed ID: 32006189
[TBL] [Abstract][Full Text] [Related]
14. Application of Electric Cell-Substrate Impedance Sensing to Investigate the Cytotoxic Effects of Andrographolide on U-87 MG Glioblastoma Cell Migration and Apoptosis.
Chiu SP; Batsaikhan B; Huang HM; Wang JY
Sensors (Basel); 2019 May; 19(10):. PubMed ID: 31100944
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).
Marks PA
Cell Cycle; 2004 May; 3(5):534-5. PubMed ID: 15020838
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays.
Barazzuol L; Jeynes JC; Merchant MJ; Wéra AC; Barry MA; Kirkby KJ; Suzuki M
Int J Radiat Biol; 2015 Jan; 91(1):90-8. PubMed ID: 25040548
[TBL] [Abstract][Full Text] [Related]
17. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
18. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
[TBL] [Abstract][Full Text] [Related]
19. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
